Clinical Trial Detail

NCT ID NCT04370704
Title Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

melanoma

Advanced Solid Tumor

Therapies

INCAGN02385 + INCAGN02390 + Retifanlimab

INCAGN02385 + INCAGN02390

Age Groups: adult senior

Additional content available in CKB BOOST